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Abstract 
Glutamate is an important signaling molecule in the nervous system and its extracellular 
levels are regulated by amino acid transporters. Studies on the role of glutamate transport 




cannot be remotely controlled with respect to the time and place of their action, which limits 
their application in cell and tissue studies. Here we show the development and evaluation of 
inhibitors of the prokaryotic transporter GltTk with photo-controlled activity, enabling the 
remote, reversible and spatiotemporally resolved regulation of transport. Based on a known 
inhibitor, TFB-TBOA, seven azo-TBOAs, bearing a photoswitchable azobenzene moiety, 
were designed and synthesized. The most promising photo-controlled inhibitor, p-MeO-azo-
TBOA, showed in its non-irradiated form an IC50 of 2.5±0.4 µM for transport by GltTk. 
Photoswitching resulted in a reversible drop of potency to an IC50 of 9.1±1.5 µM. This 3.6-
fold difference in activity was used to demonstrate that by irradiation the transporter function 
can be switched on and off reversibly. The photo-controlled inhibitors reported here could be 
a powerful tool in studying the role of glutamate transport by precisely controlling at which 





Glutamate transporters belong to a large family of membrane proteins that catalyze co-
transport of the substrate (glutamate/aspartate/neutral amino acid) and cations.[1,2] Glutamate 
is an important precursor in the biosynthesis of purines, glutamine, proline, arginine, alpha-
ketoglutarate and glutathione.[3,4] Most importantly, in the human Central Nervous System 
(CNS), glutamate is a neurotransmitter: In order to pass a signal, the pre-synaptic neuron 
releases glutamate via exocytosis, upon which glutamate is sensed by receptors on the post-
synaptic neuron.[5] Subsequently, glutamate is removed by glutamate transporters, known as 
Excitatory Amino Acid Transporters (EAATs), to attenuate the signal.[6] Accumulation of 
glutamate in the synapse results in elevated neuroplasticity and is involved in the development 




Mammalian glutamate transporters belong to the SLC1 family of membrane proteins, which is 
present in all the kingdoms of life, and includes the archaeal aspartate transporters GltPh and 
GltTk.
[1,2] Much of our understanding of the transport mechanism of the glutamate transporters 
has come from structural studies of GltPh and GltTk
[8–16] that are structurally and 
mechanistically similar to the mammalian proteins,[17,18] however can transport only aspartate, 
while EAATs can use both aspartate and glutamate as a substrate.[19]  
Mechanistic studies on the role of glutamate transport are facilitated by the use of small 
molecule inhibitors.[6][20,21] L-threo-β-Benzyloxyaspartate (TBOA) and (L-threo)-3-[3-[4-
trifluoromethyl)benzoylamino]benzyloxy]aspartate (TFB-TBOA) are aspartate derivatives 
that are most commonly used to study the role of glutamate transporters in the CNS.[22,23] An 
impressive example was published by Xie et al,[24] where a window was installed in the skull 
of a mouse that was genetically modified with a fluorescent glutamate reporter protein. Upon 
delivering a light pulse to the eye of the mouse, increased glutamate levels were observed 
shortly in the visual cortex. After injection of glutamate transporter inhibitor TBOA, the level 
of glutamate was higher and clearance was slower.[24]  
However, in experiments such as the one described above, the inhibition of glutamate 
transport by TBOA and TFB-TBOA is systemic and it cannot be excluded that compensation 
effects occur. Furthermore, due to systemic inhibition, it is difficult to study the physiology of 
glutamate transporters in a specific organ, tissue or group of cells of interest. To overcome 
this limitation, control over the activity of the inhibitor with an external stimulus would be 
highly desirable as it would allow to reversibly turn the inhibitor on and off at specific organs, 
tissues and cells at any chosen time and in a reversible manner. Such a remotely-controlled 
inhibitor would contribute to a better understanding of the role of the glutamate transporters in 
health and disease, as also exemplified by a recent report by Trauner and Kavanaugh in which 




In recent years, bio-active molecules have been developed that can be switched on and off 
with light as an external stimulus (Figure 1), along the principles of photopharmacology.[26–
28] Photo-control over biological activity can be achieved by the introduction of a molecular 
photoswitch, such as azobenzene,[29] into the structure of the molecule. Thermally stable 
trans-azobenzene (See Figure 2 in blue) is a linear, (near) flat molecule; irradiation with UV 
light results in the isomerization of the azo bond and gives cis-azobenzene, which is less 
stable, non-planar, has a higher dipole moment[29,30] and is more soluble in aqueous solutions 
then the trans isomer.[31] Trans to cis isomerization can be reversed by irradiation with visible 
light, however the cis-trans isomerization also happens spontaneously on a time-scale of 
milliseconds to years, depending on the azobenzene structure.[29,30] Since trans-azobenzene 
and cis-azobenzene strongly differ in structure and polarity, they have the potential to 
differently influence the activity of a bio-active molecule into the structure of which they have 
been incorporated. This enables the reversible photoswitching between the forms of a photo-
active molecule with different potency.[26–28] A schematic view of possible photo-control over 
glutamate transporter activity using a photo-controlled inhibitor is shown in Figure 1. The 
glutamate transporter facilitates the transport of substrate, together with sodium ions.[12,16] The 
inhibitor has two states, an inactive state (yellow) that does not bind to the transporter and an 
active state (green) that blocks transport. Light of specific wavelengths can be used to switch 
between the two states of the inhibitor and hereby a reversible photo-control over transport 
can be achieved, offering additional advantages of high spatiotemporal resolution possible in 
light delivery and the low toxicity of photons to biological systems.[27] This approach has been 
successfully demonstrated in developing photo-controlled antibiotics,[32,33] anticancer drugs 






Figure 1: Schematic view of photo-control over glutamate transporter activity, along the 
principles of photopharmacology. The yellow box represents an inactive inhibitor, which does 
not block the transport of the substrate (purple). By irradiation with light of λ1, the active 
inhibitor can be locally formed (green cylinder), which blocks substrate transport. This 
process is reversible by irradiation with wavelength λ2. 
 
Here we present the synthesis and evaluation of seven analogues of TBOA and TFB-TBOA 
with photo-controlled activity. The compounds were prepared using a key enzymatic step to 
ensure high stereocontrol in the synthesis of enantiopure precursor. Subsequently, the 
photochemical properties were studied and biological activity was determined using the 
archaeal aspartate transporter GltTk. p-MeO-azo-TBOA and p-HexO-azo-TBOA showed the 
best photochemical properties, in which nearly full conversion from trans to cis isomer can be 
achieved upon irradiation. The largest difference in activity between trans and cis isomers 
was observed for p-MeO-azo-TBOA and this difference was successfully used to reversibly 
control the transport rate by light in situ.  
 
 
2. Results and Discussion 




Our design of photoswitchable inhibitors is based on a known EAAT inhibitor TFB-TBOA 
(Figure 2), [50] which has been widely used to study glutamate transport in the CNS.[20,21] To 
render TFB-TBOA photoresponsive, we replaced the amide bond by a diazo moiety (Figure 
2), in a photopharmacological approach known as azologization.[51] An extensive SAR of 
TBOA has been described[50] on EAAT2 and EAAT3 and it demonstrated that substituents at 
the para position are beneficial for the potency. TFB-TBOA (p-CF3) has an affinity of 1.9 nM 
and 28 nM for EAAT2 and EAAT3, respectively. Other potent inhibitors disclosed in the SAR 
study have either p-HexO (1.2 nM for EAAT2, 18 nM for EAAT3), p-MeO (12 nM for 
EAAT2 and 266 nM for EAAT3) or p-CF3O (7 nM for EAAT2 and 128 nM for EAAT3) 
substituents at the para position. With those high potencies in mind, p-CF3-azo-TBOA, p-
HexO-azo-TBOA, p-MeO-azo-TBOA and p-CF3O-azo-TBOA (Figure 2) were synthesized 
and evaluated in our study. The choice of MeO and HexO substituents was further expected to 
be beneficiary, since alkyloxy substituents in the para position of azobenzene often result in 
good band separation of the isomers, enabling nearly full isomerization to cis upon 
irradiation.[52] To evaluate the importance of the position on the ring, further azo-TBOAs with 
methyl substituents on the ortho, meta and para position were designed (Figure 2). Due to the 
difference in electronic properties and structure, all the substituents likely influence both the 
biological activity of cis and trans isomers and the photochemical properties such as the 
maximum wavelength of absorption, photo-stationary states (PSS) and half-life of the cis 
isomer. Finally, we also sought to evaluate the p-CF3 substituted compound, which is the 
closest to the original TFB-TBOA structure, inspired by a recent report by Trauner and 
Kavanaugh.[25] In their study, differences in activity between trans and cis isomers were 
observed on oocytes overexpressing either EAAT1, EAAT2 or EAAT3 by measuring 
membrane voltage. The photo-controlled glutamate transporter inhibitor was more potent in 





Figure 2: TFB-TBOA and designed photoswitchable glutamate transporter inhibitors azo-
TBOAs, with the photoswitch azobenzene marked in blue. 
 
The azo-TBOAs were prepared in a convergent synthesis, where the alkylating agents 4a-g 
and the chiral building block 17 were synthesized separately and coupled at a late stage in the 
synthetic route (Figure 3). The alkylating agents 4a-g, containing the azobenzene 
photoswitch, were synthesized using standard procedures, as described in Figures S2, S3 and 
S4. The chiral building block 17 was synthesized using an enzymatic reaction, in which an 
optimized mutant of methylaspartate ammonia lyase (MAL)[53,54] stereoselectively aminates 
2-(benzyloxy)fumaric acid 13 to (2S,3S)-2-amino-3-(benzyloxy)succinic acid 14.[55] 
Subsequently, the free amine and carboxylic acid groups of compound 14 were protected and, 
after debenzylation, the reaction of the alcohol moiety in 17 with bromides 4a-g, followed by 
global deprotection, gave final compounds 1a-g (azo-TBOAs). 
Figure 3: Synthesis of azo-TBOAs 
 




Next, the photochemical properties of the azo-TBOAs were analyzed (Figure 4). As 
determined by UV/VIS spectroscopy, all compounds absorb in the UV region, where trans-p-
MeO-azo-TBOA and trans-p-HexO-azo-TBOA have an absorption maximum in DMSO of 
355 nm and 353 nm, respectively (Figures 4B, S46 and S53). All other trans-azo-TBOAs 
have an absorption maximum in the 317 - 332 nm region (Figures S41, S57, S61, S65 and 
S69), slightly more blue-shifted then p-HexO-azo-TBOA and p-MeO-azo-TBOA. All azo-
TBOAs could be switched for several cycles in DMSO with little fatigue observed (Figures 
4C, S51, S55, S59, S63, S67 and S71). Using 1H NMR spectroscopy, the photo-stationary 
states (PSS) of all azo-TBOAs in DMSO were determined, providing information on how 
much of the compound can be switched to the cis isomer upon irradiation in DMSO as a 
solvent. As expected, p-alkyloxy substituted azobenzenes p-MeO-azo-TBOA and p-HexO-
azo-TBOA showed excellent PSS: irradiation with 365 nm light results in nearly full 
isomerization to the cis isomer (Figure 4D, S56). In contrast, p-CF3O-azo-TBOA shows a 
PSS with only 71% cis present upon irradiation with 312 nm light. Irradiation of p-Me-azo-
TBOA, m-Me-azo-TBOA and o-Me-azo-TBOA resulted in a PSS containing 93%, 86% and 
90% of the cis isomer, respectively (Figure S60, S68 and S72).  
Surprisingly, p-CF3-azo-TBOA, reported earlier,[25] was in our hands unstable and small 
shifts in the spectra upon five cycles of irradiation were observed (Figure S45). When 
determining the PSS upon irradiation in DMSO by 1H NMR spectroscopy, formation of side 
products was observed (Figures S43 and S44), which was not reported before.[25] However, it 
must be noted that we used different wavelengths of irradiation (312 nm and 365 nm vs. 350 
nm[25]) and the shifts in the spectrum are mainly observed for switching in DMSO and not in 
50 mM KPi buffer (pH 7.4). For all other compounds, no photodegradation was observed. To 
confirm that the excellent switching behavior extends to biologically relevant solvents, p-
MeO-azo-TBOA was dissolved in 50 mM KPi buffer (pH 7.4) and switching was studied 




S50 and S51). To evaluate the rate of thermal cis-trans relaxation, half-lives for all 
compounds were determined in DMSO at 37 oC. For all azo-TBOAs, a half-life at 37 oC in 
DMSO of > 10 h was observed, showing that the cis isomer is relatively stable. The half-life 
of the cis isomer of p-MeO-azo-TBOA in 50 mM KPi buffer (pH 7.4) at 37 oC is 
approximately 6 h (Figure S50), which is shorter than in DMSO, but the isomer is still 
relatively stable on the timescale (4 -12 min) of the experiments that were used to evaluate the 
biological activity of azo-TBOAs (vide infra). 
 
 
Figure 4: Photochemical properties of azo-TBOAs. A: Photochemical properties of azo-
TBOAs in DMSO. B: UV/VIS spectra of p-MeO-azo-TBOA, 20 µM in DMSO, thermally 




absorbance of p-MeO-azo-TBOA at λ = 355 nm, 20 µM in DMSO, irradiated with 365 nm 
light and white light (WL). D: 1H NMR spectrum (for full spectrum, see Figure S30) of p-
MeO-azo-TBOA, 1 mg in 500 µl DMSO-d6, cis-trans ratio’s calculated from the 
1H signals of 
Ar-CH2-O (1) and O-CH-R2 (2). Top: thermal, cis-trans ratio 1:99. Bottom: irradiated with λ 
= 365 nm light for 60 min, cis-trans ratio 96:4. Right: structure of p-MeO-azo-TBOA in trans 
and cis configuration.  
 
2.3 Biological evaluation of light-switchable glutamate transporter inhibitors 
Next, the biological activity of the synthesized azo-TBOAs was determined on the aspartate 
transporter GltTk from the archaeon T. kodakarensis, that shows 32% sequence identity with 
human EAATs with even higher conservation of amino acid residues in the substrate/cation 
binding site and therefore GltTk has been used for structural and mechanistic studies.
[12] GltTk 
catalyzes uptake of aspartate coupled to the symport of three Na+ ions.[16] To study the 
inhibition of uptake by azo-TBOAs, GltTk was purified, incorporated in liposomes and the 
rate of uptake of 14C-labeled aspartate into the lumen of the liposomes was assayed [1] in the 
presence and absence of the photoswitchable inhibitors.   
For initial screening, [14C]aspartate was used at a concentration of 1 µM, and all azo-TBOAs 
were tested at 10 µM concentration, both in the dark (full trans) or irradiated (PSS) state, 
together with a negative control (no inhibitor) and a positive control (TFB-TBOA) (Figure 
5A). The uninhibited uptake rate was set at 100% transporter activity. At 10 µM concentration, 
all para-substituted trans-azo-TBOAs showed activity in the same range as TFB-TBOA, 
while trans-m-Me-azo-TBOA and trans-o-Me-azo-TBOA were less potent. This shows that 
for a better inhibitor in the trans configuration, a substituent on the para position is preferred, 
in agreement with previously reported SAR for TFB-TBOA[50]. In general, the irradiated cis 
azo-TBOAs had less inhibitory effect then the corresponding trans isomers. For p-MeO-azo-




trans forms at 10 µM and therefore the IC50 values for both cis and trans isomers were 
determined (Figure 5B), showing IC50 = 2.5 ± 0.4 µM for trans and IC50 = 9.1 ± 1.5 µM for 
cis, which represents a statistically significant 3.6-fold drop in activity upon irradiation. As 
compared to TFB-TBOA (IC50 of 0.4 ± 0.1 µM), p-MeO-azo-TBOA lost one order of 
potency due to the azologization. Since p-MeO-azo-TBOA and p-HexO-azo-TBOA have 
nearly identitical photochemical properties, also IC50 was determined for p-HexO-azo-TBOA. 
Surprisingly, for p-HexO-azo-TBOA we observed no differences in activity between trans 
and cis isomers, giving IC50 values of 0.7 ± 0.1 µM and 0.6 ± 0.1 µM, respectively. This result 
cannot be explained by differences in photoswitching between the p-MeO- and p-HexO-
substituted molecules, since in both cases the trans isomer can nearly completely be switched 
to the cis isomer. Interestingly, both isomers of p-HexO-azo-TBOA are nearly as active as 
TFB-TBOA (Figure 5b). To demonstrate that the lower activity of cis compared to trans is 
not because of an unexpected photodegradation effect, p-MeO-azo-TBOA was switched in 
several cycles in DMSO to confirm the recovery of the activity of the trans isomer (Figure 
S90).  
Besides the biological activity in the uptake assay, dissociation constants (Kd) were 
determined using Isothermal Titration Calorimetry (ITC)[16] (Figure 5C). The affinity of the 
transporter substrate aspartate and the inhibitor TFB-TBOA were determined with Kd values 
of 0.12 ± 0.03 µM and 0.86 ± 0.19 µM, respectively. For TFB-TBOA, the affinity of 0.86 ± 
0.19 µM is in the same order as the IC50 of 0.4 ± 0.1 µM, as determined by the uptake assay. 
The isomers of p-MeO-azo-TBOA have Kd of 1.89 ± 1.26 µM (Figure S93) and 3.19 ± 0.49 
µM (Figure S94), for the trans and cis form respectively, with no statistically significant 
difference between the values. Also for p-HexO-azo-TBOA no significant difference in 
binding was observed for the two isomers, where trans binds with an affinity of 2.56 ± 0.77 
µM (Figure S95) and cis with 4.99 ± 3.05 µM (Figure S96). Although the error in the ITC 




affinity to the transporter, the Kd values in the low micromolar range are consistent with the 
uptake assays. Furthermore, we expect that the observed differences in the inhibitory activity 
between the two different photoisomers may not only originate only from differences in 
binding affinity, but possibly also binding kinetics.[56] 
 
Figure 5: Biological evaluation of azo-TBOAs. A: Screening of the GltTk inhibitory activity of 
azo-TBOAs at 10 µM, dark and irradiated, error bars represent the range obtained in 
duplicate experiments, n.s. not significant, * p < 0.05. B: IC50 curves for TFB-TBOA (0.4 ± 
0.1 µM), p-MeO-azo-TBOA in trans (2.5 ± 0.4 µM), cis (9.1 ± 1.5 µM) and p-HexO-azo-
TBOA in trans (0.7 ± 0.1 µM) and cis (0.6 ± 0.1 µM), experiments performed in duplicate. C: 
Binding affinity of compounds to GltTk, determined using Isothermal Titration Calorimetry 





Reversibility and temporal control are important features of bio-active molecules with photo-
controlled activity, since they enable the control over time and place (tissue or group of cells) 
where the inhibitor is active. To test whether the 3.6-fold difference in IC50 values between 
trans and cis isomers of p-MeO-azo-TBOA is sufficient to reversibly control the transport in 
time, we attempted to photoswitch this inhibitor between the higher and lower potency states 
during the uptake assay. As shown in Figure 6A, the experiment was started with the cis 
isomer of p-MeO-azo-TBOA (weaker inhibitor) and fast uptake was observed. Upon 
irradiation with white light, the inhibitor was switched to the trans isomer (stronger inhibitor) 
and uptake was attenuated. Subsequent irradiation with UV light again resulted in switching 
to the weaker inhibitor and an increase in uptake rate was observed. The second irradiation 
with white light to the trans isomer, attenuated the uptake again. The same experiment was 
performed starting with the trans isomer (Figure 6B), showing that irradiating with UV light 
increases uptake rate and with white light decreases uptake rate, in a reversible manner. As 
controls, aspartate transport was measured with in the presence of 1 vol% DMSO, while 
continuously irradiating with UV light or with visible light (Figure S87). No changes in 
transport rate were observed, demonstrating that the proteoliposomes are not affected by light 
and further supporting the reversibility and temporal control of p-MeO-azo-TBOA over 
transport. 
Besides the ‘strong inhibitor trans’ and ‘weak inhibitor cis’ states, different cis-trans ratios 
between the thermal cis-trans ratio and the PSS ratio can be obtained by dosing the duration 
and intensity of irradiation. To demonstrate this concept, several cis-trans ratios of p-MeO-
azo-TBOA were acquired by tuning the duration of irradiation and for all mixtures their 
effect on the transport rate was measured (Figure 6C), showing a linear dependence of the 






Figure 6: Photo-control over the transport rate by switching p-MeO-azo-TBOA. A: 
Irradiation reversibly controls the transport, starting with cis-p-MeO-azo-TBOA, irradiated 
with white light (45 s) after 2.5 min, UV light (45 s) after 5.75 min and white light (45 s) after 
9 min, B: Irradiation reversibly controls the transport, starting with trans-p-MeO-azo-TBOA, 
irradiated with UV light (45 s) after 2.5 min, white light (45 s) after 5.75 min and UV light 
(45 s) after 9 min,. C: Transport rate of [14C]aspartate as a function of % trans-p-MeO-azo-






We present the design, synthesis and biological evaluation of inhibitors of the SLC1 
transporter GltTk with photo-controlled activity. Based on the known inhibitor TFB-TBOA, 
seven azo-TBOAs were synthesized using a key stereoselective enzymatic step. Of the seven 
azo-TBOAs, those with alkyloxy substituents on the para-position showed excellent PSS and 
long half-lives of the cis isomer. The largest difference in inhibitory activity was observed for 
p-MeO-azo-TBOA; the trans isomer is 3.6 fold more active compared to the cis isomer.  
Notably, p-HexO-azo-TBOA shows an excellent PSS but no difference in activity between 
cis and trans. This means that switching from trans to cis or from cis to trans has no effect on 
the biological activity, even despite the large structural change. In fact, p-MeO-azo-TBOA 
and p-HexO-azo-TBOA have nearly identical photochemical properties. Therefore, these 
compounds give insight into the relation between structure and binding to GltTk, providing 
important structural guidance in the rational design of new photo-controlled glutamate 
transporter inhibitors. 
We demonstrate the reversible and temporal control over glutamate transport using photo-
controlled inhibitors and light. Besides switching ‘on’ and ‘off’, also intermediate transport 
rates between those in the presence of full cis and full trans isomers can be achieved by 
dosing the light, demonstrating the concept of photodosimetry. Employing glutamate 
transporter inhibitors with photo-controlled activity can potentially provide a better 
understanding of the role of glutamate transporters in healthy tissues and disease pathology.  
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1.1 General remarks 
 
All chemicals for synthesis were obtained from commercial sources and used as received 
unless stated otherwise. Solvents were reagent grade. Thin-layer chromatography (TLC) was 
performed using commercial Kieselgel 60, F254 silica gel plates, and components were 
visualized with KMnO4 or phosphomolybdic acid reagent. Flash chromatography was 
performed on silica gel (Silicycle Siliaflash P60, 230-400 mesh). Drying of solutions was 
performed with MgSO4 and solvents were removed with a rotary evaporator. Chemical shifts 
for 1H NMR measurements were determined in CDCl3 relative to the tetramethylsilane 
internal standard (TMS, δ = 0.00). Chemical shifts for 13C NMR measurements were 
determined relative to the residual solvent peaks (CHCl3, δ = 77.0; DMSO-d6, δ = 40.0). The 
following abbreviations are used to indicate signal multiplicity: s, singlet; d, doublet; t, triplet; 
q, quartet; m, multiplet; br s, broad signal; app, apparent. High resolution mass spectra 
(electrospray ionisation) spectra were obtained on a Thermo scientific LTQ Orbitrap XL. 





1.2 Experimental procedures 
Synthetic route for target compounds: general overview. 
 






1.2.1 Synthesis of azobenzene-based O-alkylating agents 4a-g 
 
Figure S2: Synthesis of alkylating agent 4a. 
1-(m-tolyl)-2-(4-(trifluoromethyl)phenyl)diazene (3) 
A solution of 3-nitrosotoluene (2.56 mmol, 310 mg) and 4-trifluoromethyl-aniline 2 (3.33 
mmol, 537 mg) in acetic acid (8 mL) was heated at 50 °C overnight. The reaction mixture was 
diluted with diethyl ether (100 mL) and washed with 1 N aq. HCl (80 mL), sat. aq. NaHCO3 
(2 x 80 mL) and brine (80 mL). The organic phase was dried (MgSO4) and the solvent was 
evaporated. The product was purified by flash chromatography (Silicagel, 40-63 μm, pentane) 
to give red solid (240 mg, 36%). Rf = 0.30 (pentane); Mp. 54-55 °C; 1H NMR (400 MHz, 
CDCl3):  2.47 (s, 3H, CH3), 7.34 (d, J = 7.6 Hz, 1H, ArH), 7.43 (t, J = 8.0 Hz, 1H, ArH), 
7.74-7.83 (m, 4H, ArH), 8.00 (d, J = 8.0 Hz, 2H, ArH); 13C NMR (100 MHz, CDCl3):  21.3, 
120.8, 122.9, 123.3, 126.2, 126.3, 129.0, 132.1 (q, 2JC,F = 32.3 Hz), 132.6, 139.1, 152.5, 
154.5; 19F NMR (376 MHz, CDCl3): -62.5 (s); HRMS (ESI+) calc. for [M+H]
+ (C14H12F3N2): 
265.0947, found: 265.0942. 
 
1-(3-(bromomethyl)phenyl)-2-(4-(trifluoromethyl)phenyl)diazene (4a)  
A solution of compound 3 (0.90 mmol, 240 mg), N-bromosuccinimide (1.24 mmol, 220 mg) 
and AIBN (0.21 mmol, 35 mg) in carbon tetrachloride (9 mL) was heated at reflux for 20 h. 
Another portion of AIBN (35 mg) was added, and the reaction was heated at reflux for 




pentane – pentane/Et2O, 95:5, v/v) and recrystallization from methanol to give red needles 
(190 mg, 62% yield). Rf = 0.23 (pentane); Mp. 76-78 °C; 1H NMR (400 MHz, CDCl3):  4.59 
(s, 2H, CH2Br), 7.50-7.60 (m, 2H, ArH), 7.79 (d, J = 7.6 Hz, 2H, ArH), 7.90 (d, J = 7.6 Hz, 
1H, ArH), 7.98 (s, 1H, ArH), 8.01 (d, J = 8.0 Hz, 2H, ArH); 13C NMR (100 MHz, CDCl3):  
32.6, 123.1, 123.1,123.6, 126.3, 126.3, 129.7, 132.2, 132.4 (q, 2JC,F = 32.6 Hz), 139.1, 152.6, 
154.2; 19F NMR (376 MHz, CDCl3): -62.6 (s); HRMS (ESI+) calc. for [M+H]
+ 
(C14H11BrF3N2): 345.0032, found: 345.0033. 
 
 
Figure S3: Synthesis of alkylating agents 1b,c 
 
Ethyl (E)-3-((4-hydroxyphenyl)diazenyl)benzoate (6) 
Ethyl 3-aminobenzoate 5 (3.0 mL, 2.7 g, 17 mmol) was dissolved in aq. 1 N HCl (50 mL) and 
NaNO2 (1.60 g, 23 mmol) was added. The reaction mixture was stirred in an ice-bath for 10 
min. MeOH (25 mL) was added to the reaction mixture and a solution of PhOH (1.93 g, 14.6 
mmol) and KOH (2.14 g, 38.1 mmol) in MeOH (20 mL) was added dropwise. The reaction 
mixture was stirred at room temperature for 1h. After completion, aq. 1 N HCl (50 mL) and 
EtOAc (50 mL) were added to the reaction mixture and the aqueous layer was extracted with 




added (100 mL) and the precipitated product was filtered off and washed with pentane. The 
product was obtained as an orange solid (1.58 g, 5.8 mmol, 34% yield). Mp: 141-146 oC, 1H 
NMR (400 MHz, CDCl3) δ 1.44 (t, J = 7.1 Hz, 3H, CH3), 4.38 – 4.48 (m, 2H, CH2), 5.65 (s, 
1H, ArOH), 6.98 (d, J = 6.9 Hz, 2H, ArH), 7.58 (t, J = 7.8 Hz, 1H, ArH), 7.91 (d, J = 6.9 Hz, 
2H, ArH), 8.05 (d, J = 7.9 Hz, 1H, ArH), 8.12 (d, J = 7.7 Hz, 1H, ArH), 8.52 (s, 1H, ArH). 
13C NMR (101 MHz, CDCl3) δ 14.3, 61.4, 115.9, 123.9, 125.2, 126.4, 129.1, 131.1, 147.0, 
152.7, 158.7, 166.4. HRMS (ESI+) calc. for. [M+H+] (C15H15N2O3) 271.1077, found: 
271.1074.  
 
Ethyl (E)-3-((4-methoxyphenyl)diazenyl)benzoate (7b) 
Compound 6 (0.70 g, 2.6 mmol) was dissolved in acetone (20 mL) and MeI (3.0 mL, 1.3 g, 
9.3 mmol) and K2CO3 (3.7 g, 26.8 mmol) were added. The reaction mixture was stirred at 40 
oC overnight. After completion, Et2O (50 mL) and water (50 mL) were added and the organic 
layer was separated, dried with MgSO4 and concentrated in vacuo. The product was purified 
by flash chromatography (Silicagel 40 – 63 nm, 0-10% EtOAc in pentane). The product was 
obtained as an orange solid (0.62 g, 2.2 mmol, 85% yield). Mp: 40 - 42 oC, 1H NMR (400 
MHz, CDCl3) δ 1.42 (d, J = 14.3 Hz, 3H, CH3), 3.85 (s, 3H, OCH3), 4.42 (q, J = 7.1 Hz, 2H, 
CH2), 6.99 (d, J = 9.0 Hz, 2H, ArH), 7.54 (t, J = 7.8 Hz, 1H, ArH), 7.94 (d, J = 9.0 Hz, 2H, 
ArH), 8.11 (d, J = 7.9 Hz, 1H, ArH), 8.53 (s, 1H, ArH). 13C NMR (101 MHz, CDCl3) δ 14.4, 
55.5, 61.2, 76.8, 77.1, 77.4, 114.2, 123.9, 125.0, 126.3, 129.0, 131.0, 131.6, 146.8, 152.7, 
162.4, 166.1. HRMS (ESI+) calc. for. [M+H+] (C16H16N2O3) 285.1234, found: 285.1232.  
 
(E)-(3-((4-methoxyphenyl)diazenyl)phenyl)methanol (8b) 
Compound 7b (0.50 g, 1.8 mmol) was dissolved in dry THF (5 mL) and the reaction mixture 
was cooled in an ice-bath. LiAlH4 (1.8 mL of 1M solution in THF) was added and the 




EtOAc (50 mL), and sodium tartrate (5 g in 100 mL H2O) were added and the resulting 
mixture was stirred for 1 h. The layers were separated and the aqueous layer was extracted 
with EtOAc (3 x 20 mL). The combined organic layers were washed with water and brine, 
dried with MgSO4 and concentrated in vacuo. The product was purified by flash 
chromatography (Silicagel 40 – 63 nm, pentane, 0 - 50% Et2O in pentane) and precipitated 
with pentane. The product was obtained as an orange solid (0.27 g, 1.1 mmol, 61% yield). 
Mp: 54 - 55 oC, 1H NMR (400 MHz, CDCl3) δ 3.86 (s, 3H, OCH3), 4.74 (s, 2H, CH2OH), 
6.99 (d, J = 8.7 Hz, 2H, ArH), 7.37 – 7.50 (m, 2H, ArH), 7.75 – 7.86 (m, 2H, ArH), 7.90 (d, J 
= 8.6 Hz, 2H, ArH). 13C NMR (101 MHz, CDCl3) δ 55.6, 64.9, 114.2, 120.3, 122.3, 124.8, 
128.7, 129.2, 142.0, 146.9, 152.9, 162.1. HRMS (ESI+) calc. for. [M+H+] (C14H15N2O2) 
243.1128, found: 243.1125.  
 
(E)-1-(3-(bromomethyl)phenyl)-2-(4-methoxyphenyl)diazene (4b) 
Compound 8b (0.23 g, 0.94 mmol) was dissolved in DCM (10 mL) and NBS (0.25 g, 1.4 
mmol) and triphenylphospine (0.34 g, 1.3 mmol) were added. The reaction was stirred 
overnight at room temperature. After completion, the reaction mixture was concentrated in 
vacuo. The product was purified by flash chromatography (Silicagel 40 – 63 nm, pentane, 0 - 
5% Et2O). The product was obtained as an orange solid (0.20 g, 0.65 mmol, 69% yield). 
1H 
NMR (400 MHz, CDCl3) δ 3.88 (s, 3H, OCH3), 4.57 (s, 2H, CH2Br), 7.01 (d, J = 9.0 Hz, 2H, 
ArH), 7.47 (d, J = 6.0 Hz, 2H, ArH), 7.81 (dd, J = 6.2, 2.8 Hz, 1H, ArH), 7.87 – 7.96 (m, 3H, 
ArH). Mp: 56 - 60 oC. 13C NMR (101 MHz, CDCl3) δ 33.0, 55.6, 114.3, 122.6, 123.1, 124.9, 
129.5, 130.8, 138.8, 146.9, 153.0, 162.3. HRMS (ESI+) calc. for. [M+H+] (C14H14BrN2O2) 
305.0282, found: 305.0283.  
 




Compound 6 (0.70 g, 2,6 mmol) was dissolved in acetone (20 mL) and 1-bromohexane (3.0 
mL, 1.3 g, 9.3 mmol) and K2CO3 (3.7 g, 26.8 mmol) were added. The reaction mixture was 
stirred at 40 oC overnight. After completion, Et2O (50 mL) and water (50 mL) were added and 
the organic layer was separated, dried with MgSO4 and concentrated in vacuo. The product 
was purified by flash chromatography (Silicagel 40 – 63 nm, pentane; 0-10% EtOAc in 
pentane). The product was obtained as an orange solid (0.62 g, 2.2 mmol, 85% yield). Mp: 40 
- 42 oC, 1H NMR (400 MHz, CDCl3) δ 1.42 (d, J = 14.3 Hz, 3H, CH3), 3.85 (s, 3H, OCH3), 
4.42 (q, J = 7.1 Hz, 2H, CH2), 6.99 (d, J = 9.0 Hz, 2H, ArH), 7.54 (t, J = 7.8 Hz, 1H, ArH), 
7.94 (d, J = 9.0 Hz, 2H, ArH), 8.11 (d, J = 7.9 Hz, 1H, ArH), 8.53 (s, 1H, ArH). 13C NMR 
(101 MHz, CDCl3) δ 14.4, 55.5, 61.2, 76.8, 77.1, 77.4, 114.2, 123.9, 125.0, 126.3, 129.0, 
131.0, 131.6, 146.8, 152.7, 162.4, 166.1. HRMS (ESI+) calc. for. [M+H+] (C16H16N2O3) 
285.1234, found: 285.1232.  
 
(E)-(3-((4-hexyloxyphenyl)diazenyl)phenyl)methanol (8c) 
Compound 7c (0.61 g, 1.7 mmol) was dissolved in dry THF (5 mL) and the reaction mixture 
was cooled in an ice-bath. LiAlH4 (1.8 mL of 1M solution in THF) was added and the 
reaction mixture was stirred overnight at room temperature. After completion MeOH (5 mL), 
EtOAc (50 mL), sodium tartrate (5 g in 100 mL) were added to reaction mixture and stirred 
for 1 hour. The layers were separated and the aqueous layer was extracted with EtOAc (3 x 20 
mL). The combined organic layers were washed with water and brine, dried with MgSO4 and 
concentrated in vacuo. The product was purified by flash chromatography (Silicagel 40 – 63 
nm, pentane, 0 - 50% Et2O in pentane) and precipitated with pentane. The product was 
obtained as an orange solid (0.46 g, 1.5 mmol, 88% yield). Mp: 43 - 46 oC, 1H NMR (400 
MHz, CDCl3) δ 0.88 – 0.97 (m, 3H, CH3), 1.28 – 1.41 (m, 4H, CH2, CH2), 1.41 – 1.53 (m, 2H, 
CH2), 1.77 – 1.88 (m, 2H, CH2), 4.03 (t, J = 6.6 Hz, 2H, CH2), 4.77 (s, 2H, CH2OH), 6.99 (d, 




ArH), 7.90 (d, J = 9.0 Hz, 2H, ArH). 13C NMR (101 MHz, CDCl3) δ 14.0, 22.6, 25.7, 29.1, 
31.6, 65.0, 68.4, 114.7, 120.3, 122.3, 124.8, 128.6, 129.2, 141.9, 146.8, 153.0, 161.8. HRMS 
(ESI+) calc. for. [M+H+] (C19H25N2O2) 313.1911, found: 313.1908.  
 
(E)-1-(3-(bromomethyl)phenyl)-2-(4-hexyloxyphenyl)diazene (4c)  
Compound 8c (0.36 g, 1.2 mmol) was dissolved in DCM (10 mL) and NBS (0.24 g, 1.4 
mmol) and triphenylphospine (0.39 g, 1.5 mmol) were added. The reaction was stirred 
overnight at room temperature. After completion, the reaction mixture was concentrated in 
vacuo. The product was purified by flash chromatography (Silicagel 40 – 63 nm, pentane, 0-
5% Et2O). The product was obtained as an orange solid (0.32 g, 0.86 mmol, 72% yield). Mp: 
51 - 53 oC, 1H NMR (400 MHz, CDCl3) δ 0.92 (t, J = 6.8 Hz, 3H, CH3), 1.29 – 1.41 (m, 4H, 
CH2, CH2), 1.43 – 1.54 (m, 2H, CH2), 1.81 (p, J = 6.7 Hz, 2H, CH2), 4.03 (t, J = 6.5 Hz, 2H, 
CH2), 4.56 (s, 2H, CH2Br), 7.00 (d, J = 8.8 Hz, 2H, ArH), 7.46 (d, J = 6.0 Hz, 2H, ArH), 7.80 
(s, 1H, ArH), 7.91 (m, 3H, ArH). 13C NMR (101 MHz, CDCl3) δ 14.1, 22.6, 25.7, 29.2, 31.6, 
33.0, 68.4, 114.7, 122.6, 123.0, 124.9, 129.5, 130.7, 138.8, 146.7, 153.0, 161.9. HRMS 






Figure S4: Synthesis of alkylating agents 1d-g 
 
(E)-(3-(p-tolyldiazenyl)phenyl)methanol (11d) 
Para-toluidine 9d (1.0 g, 9.3 mmol) was dissolved in DCM (20 mL) and water (100 mL) and 
Oxone (5.2 g, 19 mmol) was added. The reaction mixture was stirred at room temperature for 
85 min. After completion, DCM (20 mL) was added and the aqueous layer was extracted with 
DCM (3 x 20 mL). The combined organic layers were washed with sat. aq. NaHCO3, 1 N HCl 
and brine and concentrated in vacuo. The crude product was flushed over a silica gel column 
(Silicagel 40 – 63 nm, pentane). Without further purification, the crude product (0.18 g, 1.4 
mmol) was dissolved in acetic acid (5 mL) and (3-aminophenyl)methanol (0.3 g, 2.4 mmol) 
was added. The reaction mixture was stirred at 40 oC overnight. After completion EtOAc (15 
mL) and sat aq. NaHCO3 (10 mL) were added and the reaction mixture was stirred overnight. 
EtOAc (50 mL) and water (50 mL) were added and the aqueous layer was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with sat. aq. NaHCO3, 1 N 
HCl and brine, dried with MgSO4 and concentrated in vacuo. The product was purified by 
flash chromatography (Silicagel 40 – 63 nm, pentane; 0 – 50% Et2O). The product was 
obtained as an orange solid (0.17 g, 0.8 mmol, 51% yield over two steps). Mp: 66 - 68 oC, 1H 
NMR (400 MHz, CDCl3) δ 2.40 (s, 4H, CH3, OH), 4.71 (s, 2H, CH2OH), 7.28 (d, J = 8.1 Hz, 




64.8, 120.5, 122.4, 122.9, 129.1, 129.2, 129.8, 141.7, 142.0, 150.7, 152.8. HRMS (ESI+) calc. 
for. [M+H+] (C14H15N2O) 227.1180, found: 227.1176.  
(E)-1-(3-(bromomethyl)phenyl)-2-(p-tolyl)diazene (4d) 
Compound 11d (0.15 g, 0.66 mmol) was dissolved in DCM (10 mL) and NBS (0.18 g, 1.0 
mmol) and triphenylphosphine (0.25 g, 0.95 mmol) were added. The reaction was stirred at 
room temperature overnight. After completion, the reaction mixture was concentrated in 
vacuo. The product was purified by flash chromatography (Silicagel 40 – 63 nm, pentane; 0 – 
5% Et2O). The product was obtained as an orange solid (0.12 g, 0.42 mmol, 63% yield). Mp: 
68 - 69 oC, 1H NMR (400 MHz, CDCl3) δ 2.42 (s, 3H, CH3), 4.55 (s, 2H, CH2Br), 7.30 (d, J = 
8.2 Hz, 2H, ArH), 7.46 (d, J = 5.2 Hz, 2H, ArH), 7.83 (d, J = 8.2 Hz, 3H, ArH), 7.91 (s, 1H, 
ArH). 13C NMR (101 MHz, CDCl3) δ 21.6, 32.9, 122.8, 123.0, 123.2, 129.5, 129.8, 131.1, 




4-(trifluoromethoxy)aniline 9e (2.00 g, 11.3 mmol) was dissolved in DCM (20 mL) and water 
(100 mL) and Oxone (8.0 g, 26 mmol) was added. The reaction mixture was stirred at room 
temperature for 1 h. After completion, DCM (20 mL) was added and the aqueous layer was 
extracted with DCM (3 x 20 mL). The combined organic layers were washed with sat. aq. 
NaHCO3, 1 N HCl and brine and concentrated in vacuo. The crude product was flushed over a 
silica gel column (Silicagel 40 – 63 nm, pentane). Without further purification, the crude 
product (0.73 g, 2.5 mmol) was dissolved in acetic acid (20 mL) and (3-
aminophenyl)methanol (1.5 g, 5.1 mmol) was added. The reaction mixture was stirred at 40oC 




reaction mixture was stirred overnight. EtOAc (50 mL) and water (50 mL) were added and 
the aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic layers were 
washed with sat. aq. NaHCO3, 1 N HCl and brine, dried with MgSO4 and concentrated in 
vacuo. The product was purified by flash chromatography (Silicagel 40 – 63 nm, pentane; 0 – 
30% Et2O). The product was obtained as orange solid (0.73 g, 2.5 mmol, 22% yield). Mp: 47 - 
48 oC, 1H NMR (400 MHz, CDCl3) δ 4.79 (s, 2H, CH2OH), 7.34 (d, J = 8.8 Hz, 2H, ArH), 
7.50 (d, J = 6.8 Hz, 2H, ArH), 7.83 (d, J = 7.0 Hz, 1H, ArH), 7.90 (s, 1H, ArH), 7.95 (d, J = 
8.7 Hz, 2H, ArH). 13C NMR (101 MHz, CDCl3) δ 152.6, 150.9, 150.6, 142.1, 129.7, 129.3, 
124.4, 122.7, 121.3, 120.7, 64.8. 19F NMR (376 MHz, CDCl3) δ -57.7. HRMS (ESI+) calc. for. 
[M+H+] (C14H12F3N2O2) 297.0844, found: 297.0844.  
 
(E)-1-(3-(bromomethyl)phenyl)-2-(4-(trifluoromethoxy)phenyl)diazene (4e)  
Compound 11e (0.3 g, 1 mmol) was dissolved in DCM (10 mL) and NBS (0.29 g, 1.6 mmol) 
and triphenylphosphine (0.33 g, 1.3 mmol) were added. The reaction was stirred at room 
temperature overnight. After completion, the reaction mixture was concentrated in vacuo. The 
product was purified by flash chromatography (Silicagel 40 – 63 nm, pentane; 0 – 5% Et2O). 
The product was obtained as an orange solid (0.31 g, 0.85 mmol, 83% yield). Mp: 64 - 67 oC, 
1H NMR (400 MHz, CDCl3) δ 4.58 (s, 2H, CH2Br), 7.36 (d, J = 8.2 Hz, 2H, ArH), 7.52 (d, J 
= 7.0 Hz, 2H, ArH), 7.86 (d, J = 6.8 Hz, 1H, ArH), 7.92 – 8.01 (m, 3H, ArH). 13C NMR (101 
MHz, CDCl3) δ 32.7, 121.3, 123.0, 123.4, 124.4, 129.6, 131.7, 139.0, 150.6, 151.1, 152.6. 
19F 
NMR (376 MHz, CDCl3) δ -57.7. HRMS (ESI+) calc. for. [M+H
+] (C14H11BrF3N2O
+) Exact 





Meta-toluidine 9f (1.0 g, 9.3 mmol) was dissolved in DCM (20 mL) and water (100 mL) and 
Oxone (5.2 g, 19 mmol) was added. The reaction mixture was stirred at room temperature for 
90 min. After completion, DCM (20 mL) was added and the aqueous layer was extracted with 
DCM (3 x 20 mL). The combined organic layers were washed with sat. aq. NaHCO3, 1 N HCl 
and brine and concentrated in vacuo. The crude product was flushed over a silica gel column 
(Silicagel 40 – 63 nm, pentane). Without further purification, the crude product (0.18 g, 1.4 
mmol) was dissolved in acetic acid (5 mL) and (3-aminophenyl)methanol (0.30 g, 2.4 mmol) 
was added. The reaction mixture was stirred at 40oC overnight. After completion EtOAc (15 
mL) and sat aq. NaHCO3 (10 mL) were added and the reaction mixture was stirred overnight. 
EtOAc (50 mL) and water (50 mL) were added and the aqueous layer was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with sat. aq. NaHCO3, 1 N 
HCl and brine, dried with MgSO4 and concentrated in vacuo. The product was purified by 
flash chromatography (Silicagel 40 – 63 nm, pentane; 0 – 50% Et2O). The product was 
obtained as orange oil (0.17 g, 0.8 mmol, 51% yield over two steps). 1H NMR (400 MHz, 
CDCl3) δ 2.41 (s, 3H, CH3), 2.77 (s, 1H, OH), 4.69 (s, 2H, CH2OH), 7.25 (d, J = 7.8 Hz, 1H, 
ArH), 7.33 – 7.46 (m, 3H, ArH), 7.69 (d, J = 6.4 Hz, 2H, ArH), 7.79 (d, J = 7.5 Hz, 1H, ArH), 
7.83 (s, 1H, ArH). 13C NMR (101 MHz, CDCl3) δ 21.4, 64.7, 120.5, 120.6, 122.5, 123.0, 
128.9, 129.2, 129.3, 131.9, 139.0, 142.1, 152.7, 152.8. HRMS (ESI+) calc. for. [M+H+] 
(C14H15N2O) 227.1180, found: 227.1179.  
 
(E)-1-(3-(bromomethyl)phenyl)-2-(m-tolyl)diazene (4f) 
Compound 11f (0.15 g, 0.66 mmol) was dissolved in DCM (10 mL) and NBS (0.18 g, 1.0 




room temperature overnight. After completion, the reaction mixture was concentrated in 
vacuo. The product was purified by flash chromatography (Silicagel 40 – 63 nm, pentane; 0 – 
5% Et2O). The product was obtained as an orange oil (0.12 g, 0.42 mmol, 63% yield) 
1H 
NMR (400 MHz, CDCl3) δ 2.49 (s, 3H, CH3), 4.59 (s, 2H, CH2Br), 7.33 (d, J = 7.7 Hz, 1H, 
ArH), 7.45 (t, J = 8.0 Hz, 1H, ArH), 7.52 (m, 2H, ArH), 7.80 (m, 2H, ArH), 7.91 (m, 1H, 
ArH), 7.99 (s, 1H, ArH) 13C NMR (101 MHz, CDCl3) δ 21.5, 32.9, 120.7, 122.9, 123.3, 129.0, 
129.6, 131.4, 132.1, 139.0, 152.6, 152.9. HRMS (ESI+) calc. for. [M+H+] (C14H15BrN2) 
289.0335, found: 289.0335.  
 
(E)-(3-(o-tolyldiazenyl)phenyl)methanol (11g) 
Ortho-toluidine 9g (1.0 ml, 1.0 g, 9.3 mmol) was dissolved in DCM (20 mL) and water (100 
mL) and Oxone (5.2 g, 19 mmol) was added. The reaction mixture was stirred at room 
temperature for 20 min. After completion, DCM (20 mL) was added and the aqueous layer 
was extracted with DCM (3 x 20 mL). The combined organic layers were washed with sat. aq. 
NaHCO3, 1 N HCl and brine and concentrated in vacuo. The crude product was flushed over a 
silica gel column (Silicagel 40 – 63 nm, pentane). Without further purification, the crude 
product (0.20 g, 1.7 mmol) was dissolved in acetic acid (5 mL) and (3-aminophenyl)methanol 
(0.3 g, 2.4 mmol) was added. The reaction mixture was stirred at 40oC overnight. After 
completion EtOAc (15 mL) and sat aq. NaHCO3 (10 mL) were added and the reaction 
mixture was stirred overnight. EtOAc (50 mL) and water (50 mL) were added and the 
aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic layers were 
washed with sat. aq. NaHCO3, 1 N HCl and brine, dried with MgSO4 and concentrated in 
vacuo. The product was purified by flash chromatography (Silicagel 40 – 63 nm, pentane, 




over two steps). 1H NMR (400 MHz, CDCl3) δ 2.70 (s, 3H, CH3), 4.72 (s, 2H, CH2Br), 7.24 (t, 
J = 7.0 Hz, 1H, ArH), 7.33 (m, 2H, ArH), 7.38 – 7.48 (m, 2H, ArH), 7.60 (d, J = 8.0 Hz, 1H, 
ArH), 7.81 (d, J = 7.5 Hz, 1H), 7.86 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 17.6, 64.8, 115.5, 
121.1, 122.3, 129.2, 129.2, 131.0, 131.3, 138.1, 142.0, 150.7, 153.1. HRMS (ESI+) calc. for. 
[M+H+] (C14H15N2O): 227.1180, found: 227.1176.  
 
(E)-1-(3-(bromomethyl)phenyl)-2-(o-tolyl)diazene (4g) 
Compound 11g (0.15 g, 0.66 mmol) was dissolved in DCM (10 mL) and NBS (0.16 g, 0.9 
mmol) and triphenylphosphine (0.24 g, 0.92 mmol) were added. The reaction was stirred at 
room temperature overnight. After completion, the reaction mixture was concentrated in 
vacuo. The product was purified by flash chromatography (Silicagel 40 – 63 nm, pentane; 0 – 
5% Et2O). The product was obtained as an orange solid (0.11 g, 0.38 mmol, 57% yield). Mp: 
46 - 48 oC, 1H NMR (400 MHz, CDCl3) δ 2.73 (s, 3H, CH3), 4.59 (s, 2H, CH2Br), 7.28 (d, J = 
8.1 Hz, 1H, ArH), 7.32 – 7.40 (m, 2H, ArH), 7.50 (m, 2H, ArH), 7.63 (d, J = 8.3 Hz, 1H), 
ArH, 7.82 – 7.89 (m, 1H, ArH), 7.93 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 17.5, 32.9, 
115.4, 123.1, 123.3, 126.4, 129.5, 131.2, 131.3, 138.3, 138.8, 150.6, 153.2. HRMS (ESI+) 











1.2.2 Synthesis of chiral building block 17 
 
Figure S5: Synthesis of alkylating agent 17 
 
trans-2-benzyloxy fumaric acid (13) 
To a stirred solution of dimethyl acetylenedicarboxylate (12, 14.2 g, 100 mmol) in DCM (250 
mL), DABCO (1.1 g, 10 mmol) and benzyl alcohol (10.8 g, 100 mmol) were added and the 
reaction mixture was stirred at room temperature. After completion of the reaction (TLC 
monitoring), the solvent was removed under vacuum to provide crude products as a dark oil, 
which contained trans and cis isomers (trans/cis = 6/4). The crude product was dissolved in 
ethanol (300 mL) and subjected to basic hydrolysis using 2 M NaOH (300 mL) at reflux for 2 
h. After complete hydrolysis, the reaction mixture was cooled to room temperature and 
extracted using EtOAc (2 x 300 mL). The aqueous layer was acidified with HCl (con.) until 
pH = 1 (ice-bath) and extracted with EtOAc (3 x 300 mL). The combined organic layers were 
washed with brine (2 x 500 mL), dried over anhydrous Na2SO4 and evaporated to provide a 
dark yellow solid. Recrystallization was performed using hexane/Et2O (v/v = 1/3) to provide 
pure trans-2-benzyloxy-fumaric acid 13 (8.5 g, 38 mmol yield 38% over 2 steps). 1H NMR 
(500 MHz, DMSO-d6) δ 5.10 (s, 2H, CH2), 6.08 (s, 1H, CH), 7.43 – 7.32 (m, 5H, ArH). The 





(L-threo)-3-benzyloxyaspartate (14, L-TBOA) 
To a slowly stirred solution of trans-2-benzyloxy-fumaric acid 13 (2.4 g, 11 mmol) in 220 mL 
of buffer (5 M NH3/NH4Cl, 20 mM MgCl2, pH = 9.5) was added MAL L384A
1 (0.01 mol%, 5 
mL, 12.3 mg/mL), and the reaction mixture was incubated for 24 hours at room temperature. 
After completion of the enzymatic reaction (1H NMR monitoring, >98% conversion), the 
reaction mixture was warmed up to 60 °C for 10 min until the enzyme precipitated, followed 
by filtration through cotton to remove the white precipitates. Most of the water in the reaction 
mixture was evaporated under vacuum, then the resulting concentrated mixture was acidified 
with HCl (conc.) to pH = 1 (ice-bath). The acidified solution was loaded onto a column 
packed with cation-exchange resin (1000 g of Dowex 50W X8, 50-100 mesh), which was pre-
treated with 2 M aqueous ammonia (4 column volumes), 1 M HCl (2 column volumes) and 
distilled water (4 column volumes). The column was washed with water (2 column volumes) 
and the product was eluted with 2 M aqueous ammonia (2 column volumes). The ninhydrin-
positive fractions were collected and lyophilized to yield the product L-TBOA (14) as 
ammonium salt (white powder, 2.3 g, 8.8 mmol, 80% yield). 1H NMR (500 MHz, D2O) δ 3.99 
(d, J = 2.3 Hz, 1H, CH), 4.32 (d, J = 2.3 Hz, 1H, CH), 4.47 (d, J = 11.6 Hz, 1H, BnH), 4.71 
(d, J = 11.6 Hz, 1H, BnH), 7.43 – 7.34 (m, 5H, ArH). The 1H NMR spectra are in agreement 
with published data.1  
 
(L-threo)-dimethyl 2-amino-3-(benzyloxy)succinate hydrochloride (15)  
To a stirred suspension of L-TBOA (14, 1.6 g, 6.2 mmol) in dry MeOH (30 mL) at was added 
SOCl2 (4.5 mL, 62 mmol) dropwise (in an ice-bath). After 20 minutes, the cooling system was 
removed and the reaction mixture was heated to reflux for 8 h. After completion of the 
reaction (TLC monitoring), the reaction mixture was cooled to room temperature, and solvent 
was removed to provide crude product 15 as a white solid (1.8 g, 95%). No purification was 





(L-threo)-dimethyl 2-(benzyloxy)-3-[(tert-butoxycarbonyl)amino]succinate (16) 
To a stirred solution of 15 (1.8 g, 5.9 mmol) in dry DCM (50 mL) was added DIEA (1.5 mL, 
9.1 mmol) and Boc2O (1.6 g, 7.4 mmol) under cooling in an ice-bath. After 10 minutes, the 
cooling was removed and the reaction mixture was stirred at room temperature for further 24 
h. After completion of the reaction, the reaction mixture was diluted with DCM (50 mL), and 
washed with 0.5 M HCl (50 mL), saturated NaHCO3 solution (100 mL) and brine (100 mL). 
The organic layer was dried over Na2SO4 and concentrated under vacuum to give crude 
product 16 as a clear oil (2.0 g, 5.3 mmol, 90% yield). No purification was needed, product 16 
was directly used for the next step. 1H NMR (500 MHz, DMSO-d6) δ 1.36 (s, 9H, Boc-H9), 
3.60 (s, 3H, OCH3), 3.67 (s, 3H, OCH3), 4.42 (d, J = 11.9 Hz, 1H, BnH), 4.47 (d, J = 4.3 Hz, 
1H, CH), 4.62 (dd, J = 9.5, 4.3 Hz, 1H, CH), 4.67 (d, J = 11.9 Hz, 1H, BnH), 7.05 (d, J = 9.5 
Hz, 1H, NH), 7.28 – 7.36 (m, 5H, ArH). The 1H NMR spectra are in agreement with 
published data.2  
 
(L-threo)-dimethyl 2-[(tert-butoxycarbonyl)amino]-3-hydroxy succinate (17) 
To a stirred solution of 16 (2.0 g, 5.4 mmol) in dry MeOH (50 mL) was added Pd/C (10%, 1.8 
g) and HCOONH4 (2.5 g). The mixture was heated to reflux for 45 min. After completion of 
the reaction (TLC monitoring), the reaction mixture was filtered through Celite and 
evaporated under vacuum to provide crude product 17. Purification was conducted via flash 
chromatography (EtOAc : petroleum ether, 1:4, v/v) to provide compound 17 as clear oil (1.2 
g, 4.3 mmol, 80% yield). 1H NMR (500 MHz, CDCl3) δ 1.42 (s, 9H, Boc-H9), 3.22 (d, J = 5.7 
Hz, 1H, OH), 3.80 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 4.69 (dd, J = 5.8, 2.0 Hz, 1H, CH), 
4.78 (dd, J = 9.3, 2.0 Hz, 1H, CH), 5.29 (d, J = 9.5 Hz, 1H, NH). 13C NMR (126 MHz, 
CDCl3) δ 28.2, 52.9, 53.2, 56.1, 71.1, 80.4, 155.3, 169.8, 172.4. HRMS (ESI+): calc. for 




1.2.3 Synthesis of final compounds 1a-g 
 
Figure S6: Synthesis of azo-TBOAs 1a-g 
 
(L-threo)-trans-dimethyl 2-((tert-butoxycarbonyl)amino)-3-(3-((4-(trifluoromethyl)-
phenyl)diazenyl)benzyloxy) succinate (18a) 
Compound 17 (80 mg, 0.29 mmol) and 4a (200 mg, 0.56 mmol) were dissolved in DMF (2 
mL) under -20 oC and stirred over 10 min. NaH (60% in mineral oil, 11.6 mg, 0.29 mmol) 
was added, and the reaction mixture was stirred at -20 oC for 2 h. Afterwards, it was warmed 
to 0 oC (ice bath) and the stirring continued for another 2 h. The reaction mixture was 
quenched with cold water and then extracted with EtOAc (3 x 20 mL). The collected organic 
phases were washed with brine (3 x 50 mL), and dried with Na2SO4. The volatiles were 
evaporated and the product was purified by flash chromatography (EtOAc : petroleum ether, 
9:91, v/v) to provide pure 18a as yellow oil (72 mg, 46% yield). 1H NMR (500 MHz, CDCl3) 
δ 1.43 (s, 9H, Boc-H9), 3.66 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 4.49 (d, J = 12.0 Hz, 1H, 




1H, BnH), 5.37 (d, J = 10.0 Hz, 1H, NH), 7.43 (d, J = 7.6 Hz, 1H, ArH), 7.52 (t, J = 7.7 Hz, 
1H, ArH), 7.79 (d, J = 8.3 Hz, 2H, ArH), 7.84 (s, 1H, ArH), 7.90 (d, J = 7.9 Hz, 1H, ArH), 
8.00 (d, J = 8.2 Hz, 2H, ArH). 13C NMR (126 MHz, CDCl3) δ 28.3, 52.7, 52.9, 56.2, 72.4, 
77.4, 80.5, 122.6, 123.2, 123.3, 124.0 (q, J = 272.2 Hz), 126.5 (q, J = 3.8 Hz), 129.5, 131.4, 
132.5 (q, J = 31.5 Hz), 138.2, 152.6, 154.4, 155.6, 169.7, 169.8. HRMS (ESI+) calc for 




To a solution of 18a (65 mg, 0.12 mmol) in dry DCM (2 mL), cooled in an ice-bath, 
trifluoroacetic acid (0.8 mL) was added dropwise. After 10 min, the ice-bath was removed 
and the reaction mixture was stirred at room temperature for 1.5 h until all the starting 
materials were consumed (TLC monitor). Volatiles were removed in vacuo to provide product 
19a which was used in the next step without further purification. Compound 19a was 
dissolved in THF (1 mL) and water (1 mL) and LiOH (17 mg, 0.72 mmol) was added. The 
reaction mixture was stirred at room temperature for 2 h. Volatiles were removed in vacuo 
and, residue was washed with EtOAc (1 mL) and acidified with 1 M HCl until yellow 
precipitates appeared. The precipitate was filtered off, washed with cold water and dried 
under vacuum overnight to provide the final product 1a as yellow solid (25 mg, 50% yield 
over two steps). 1H NMR (400 MHz, DMSO-d6) δ 3.71 (d, J = 7.5 Hz, 1H, CH), 4.16 (d, J = 
7.5 Hz, 1H, CH), 4.58 (d, J = 11.5 Hz, 1H, BnH), 4.88 (d, J = 11.5 Hz, 1H, BnH), 7.58 (t, J = 
7.7 Hz, 1H, ArH), 7.67 (d, J = 7.5 Hz, 1H, ArH), 7.85 (d, J = 7.9 Hz, 1H, ArH), 8.97 – 8.00 
(m, 3H, ArH), 8.07 (d, J = 8.4 Hz, 2H, ArH); 13C NMR (101 MHz, DMSO-d6) δ 53.8, 71.5, 




168.3, 171.1. One Carbon is missing due to CF3. 
19F NMR (376 MHz, DMSO-d6) δ -56.7 (s). 
HRMS (ESI+) calc for [M+H]+: (C18H17F3N3O5) 412.1115, found 412.1114. 
 
(L-threo)-trans-dimethyl 2-((tert-butoxycarbonyl)amino)-3-(3-((4-(methoxy)-
phenyl)diazenyl)benzyloxy) succinate (18b) 
Compound 17 (90 mg, 0.32 mmol) and 4b (195 mg, 0.64 mmol) were dissolved in DMF (2 
mL) under -20 oC and stirred over 10 min. NaH (60% in mineral oil, 12.8 mg, 0.32 mmol) 
was added, and the reaction mixture was stirred at -20 oC for 2 h. Afterwards, it was warmed 
to 0 oC (ice bath) and the stirring continued for another 2 h. The reaction mixture was 
quenched with cold water and then extracted with EtOAc (3 x 20 mL). The collected organic 
phases were washed with brine (3 x 50 mL), and dried with Na2SO4. The volatiles were 
evaporated and the product was purified by flash chromatography (EtOAc : petroleum ether, 
18:82, v/v) to provide pure 18b as yellow oil (53 mg, 33% yield). 1H NMR (500 MHz, 
CDCl3) δ 1.43 (s, 9H, Boc-H9), 3.64 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 
4.47 (d, J = 12.1 Hz, 1H, BnH), 4.54 (d, J = 2.4 Hz, 1H, CH), 4.83 (dd, J = 10.0, 2.0 Hz, 1H, 
CH), 4.93 (d, J = 12.1 Hz, 1H, BnH), 5.38 (d, J = 9.9 Hz, 1H, NH), 7.02 (d, J = 8.8 Hz, 2H, 
ArH), 7.34 (d, J = 7.5 Hz, 1H, ArH), 7.45 – 7.48 (m, 1H, ArH), 7.75 (s, 1H, ArH), 7.81 – 
7.84 (m, 1H, ArH), 7.91 – 7.94 (m, 2H, ArH); 13C NMR (126 MHz, CDCl3) δ 28.34, 52.6, 
52.9, 55.8, 56.2, 65.2, 72.5, 77.1, 114.4, 120.4, 122.2, 122.7, 125.0, 128.9, 129.3, 130.1, 137.9, 









To a solution of 18b (53 mg, 0.11 mmol) in dry DCM (2 mL), cooled in an ice-bath, 
trifluoroacetic acid (0.8 mL) was added dropwise. After 10 min, the ice-bath was removed 
and the reaction mixture was stirred at room temperature for 1.5 h until all the starting 
materials were consumed (TLC monitor). Volatiles were removed in vacuo to provide product 
19b which was used in the next step without further purification. Compound 19b was 
dissolved in THF (1 mL) and water (1 mL) and LiOH (16 mg, 0.66 mmol) was added. The 
reaction mixture was stirred at room temperature for 2 h. Volatiles were removed in vacuo 
and, residue was washed with EtOAc (1 mL) and acidified with 1 M HCl until yellow 
precipitates appeared. The precipitate was filtered off, washed with cold water and dried 
under vacuum overnight to provide the final product 1b as yellow solid (25 mg, 61% yield 
over two steps). 1H NMR (400 MHz, DMSO-d6) δ 3.86 – 3.89 (m, 4H, CH and OCH3), 4.17 
(dd, J = 9.7, 1.4 Hz, 1H, CH), 4.59 (d, J = 10.9 Hz, 1H, BnH), 4.94 (d, J = 10.9 Hz, 1H, BnH), 
7.13 – 7.16 (m, 2H, ArH), 7.53 (t, J = 7.7 Hz, 1H, ArH), 7.60 (d, J = 7.6 Hz, 1H, ArH), 7.76 
(d, J = 7.9 Hz, 1H, ArH), 7.90 – 7.93 (m, 3H, ArH); 13C NMR (101 MHz, DMSO-d6) δ 53.2, 
55.7, 72.4, 75.1, 114.7, 121.2, 122.2, 124.6, 129.1, 130.5, 139.3, 146.2, 152.0, 162.1, 168.5, 
170.7. HRMS (ESI+) calc. for [M+H]+ (C18H20N3O6) 374.1347, found 374.1350. 
 
(L-threo)-trans-dimethyl 2-((tert-butoxycarbonyl)amino)-3-(3-((4-(hexyloxy)-
phenyl)diazenyl)benzyloxy) succinate (18c) 
Compound 17 (90 mg, 0.32 mmol) and 4a (244 mg, 0.64 mmol) were dissolved in DMF (2 




was added, and the reaction mixture was stirred at -20 oC for 2 h. Afterwards, it was warmed 
to 0 oC (ice bath) and the stirring continued for another 2 h. The reaction mixture was 
quenched with cold water and then extracted with EtOAc (3 x 20 mL). The collected organic 
phases were washed with brine (3 x 50 mL), and dried with Na2SO4. The volatiles were 
evaporated and the product was purified by flash chromatography (EtOAc : petroleum ether, 
10:90, v/v) to provide pure 18c as yellow oil (58 mg, 32% yield). 1H NMR (500 MHz, 
CDCl3) δ 0.92 (t, J = 6.7 Hz, 3H, CH3), 1.34 – 1.37 (m, 4H, CH2, CH2), 1.43 (s, 9H, Boc-H9), 
1.46 – 1.50 (m, 2H, CH2), 1.79 – 1.85 (m, 2H, CH2), 3.63 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 
4.04 (t, J = 6.5 Hz, 2H, OCH2), 4.47 (d, J = 12.2 Hz, 1H, BnH), 4.54 (d, J = 2.5 Hz, 1H, CH), 
4.82 – 4.84 (m, 1H, CH), 4.92 (d, J = 12.2 Hz, 1H, BnH), 5.38 (d, J = 10.0 Hz, 1H, NH), 6.99 
– 7.01 (m, 2H, ArH), 7.33 (d, J = 7.2 Hz, 1H, ArH), 7.47 (t, J = 7.7 Hz, 1H, ArH), 7.75 (s, 1H, 
ArH), 7.82 (d, J = 7.4 Hz, 1H, ArH), 7.89 – 7.91 (m, 2H, ArH); 13C NMR (126 MHz, CDCl3) 
δ 14.2, 22.8, 25.8, 28.3, 29.3, 31.7, 52.6, 52.9, 56.2, 68.5, 72.5, 77.1, 80.4, 114.9, 122.1, 122.7, 
124.9, 129.3, 130.1, 137.8, 146.9, 153.0, 155.6, 162.0, 169.8. One C is missing due to overlap 




To a solution of 18c (58 mg, 0.10 mmol) in dry DCM (2 mL), cooled in an ice-bath, 
trifluoroacetic acid (0.8 mL) was added dropwise. After 10 min, the ice-bath was removed 
and the reaction mixture was stirred at room temperature for 1.5 h until all the starting 
materials were consumed (TLC monitor). Volatiles were removed in vacuo to provide 
intermediate 19c which was used in the next step without further purification. Compound 19c 




The reaction mixture was stirred at room temperature for 2 h. Volatiles were removed in 
vacuo and, residue was washed with EtOAc (1 mL) and acidified with 1 M HCl until yellow 
precipitates appeared. The precipitate was filtered off, washed with cold water and dried 
under vacuum overnight to provide the final product 1c as yellow solid (23 mg, 52% yield 
over two steps). 1H NMR (400 MHz, DMSO-d6) δ 0.89 (t, J = 8.5 Hz, 3H, CH3), 1.29 – 1.36 
(m, 4H, CH2, CH2), 1.40 – 1.47 (m, 2H, CH2), 1.75 (p, J = 6.7 Hz, 2H, CH2), 3.86 (d, J = 9.6 
Hz, 1H, CH), 4.08 (t, J = 6.5 Hz, 2H, OCH2), 4.16 (d, J = 9.6 Hz, 1H, CH), 4.59 (d, J = 11.0 
Hz, 1H, BnH), 4.94 (d, J = 10.9 Hz, 1H, BnH), 7.12 – 7.14 (m, 2H, ArH), 7.53 (t, J = 7.7 Hz, 
1H, ArH), 7.59 (d, J = 7.3 Hz, 1H, ArH), 7.75 (d, J = 7.9 Hz, 1H, ArH), 7.88 – 7.93 (m, 3H, 
ArH); 13C NMR (101 MHz, DMSO-d6) δ 14.0, 22.1, 25.2, 28.6, 31.0, 53.2, 68.1, 72.3, 75.1, 
115.1, 121.1, 122.1, 124.6, 129.0, 130.4, 139.3, 146.1, 152.0, 161.5, 168.4, 170.6. HRMS 
(ESI+) calc. for [M+H]+ (C23H30N3O6) 444.2129, found 444.2134. 
 
(L-threo)-trans-dimethyl 2-((tert-butoxycarbonyl)amino)-3-(3-((4-(methyl)-
phenyl)diazenyl)benzyloxy) succinate (18d) 
Compound 17 (77 mg, 0.28 mmol) and 4d (120 mg, 0.42 mmol) were dissolved in DMF (2 
mL) under -20 oC and stirred over 10 min. NaH (60% in mineral oil, 11.2 mg, 0.28 mmol) 
was added, and the reaction mixture was stirred at -20 oC for 2 h. Afterwards, it was warmed 
to 0 oC (ice bath) and the stirring continued for another 2 h. The reaction mixture was 
quenched with cold water and then extracted with EtOAc (3 x 20 mL). The collected organic 
phases were washed with brine (3 x 50 mL), and dried with Na2SO4. The volatiles were 
evaporated and the product was purified by flash chromatography (EtOAc : petroleum ether, 
10:90, v/v) to provide pure 18d as yellow oil (42 mg, 31% yield). 1H NMR (500 MHz, 
CDCl3) δ 1.43 (s, 9H, Boc-H9), 2.44 (s, 3H, CH3), 3.64 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 




CH), 4.93 (d, J = 12.1 Hz, 1H, BnH), 5.38 (d, J = 9.9 Hz, 1H, NH), 7.32 (d, J = 8.0 Hz, 2H, 
ArH), 7.36 (dt, J = 7.4, 1.3 Hz, 1H, ArH), 7.49 (t, J = 7.7 Hz, 1H, ArH), 7.77 (d, J = 1.9 Hz, 
1H, ArH), 7.84 (dd, J = 11.6, 8.7 Hz, 3H, ArH); 13C NMR (126 MHz, DMSO-d6) δ 21.1, 28.0, 
52.1, 52.4, 55.6, 71.5, 77.5, 78.8, 121.6, 121.8, 122.6, 129.3, 130.0, 130.4, 138.9, 141.9, 150.0, 





To a solution of 18d (42 mg, 0.087 mmol) in dry DCM (2 mL), cooled in an ice-bath, 
trifluoroacetic acid (0.8 mL) was added dropwise. After 10 min, the ice-bath was removed 
and the reaction mixture was stirred at room temperature for 1.5 h until all the starting 
materials were consumed (TLC monitor). Volatiles were removed in vacuo to provide product 
19d which was used in the next step without further purification. Compound 19d was 
dissolved in THF (1 mL) and water (1 mL) and LiOH (12.5 mg, 0.52 mmol) was added. The 
reaction mixture was stirred at room temperature for 2 h. Volatiles were removed in vacuo 
and, residue was washed with EtOAc (1 mL) and acidified with 1 M HCl until yellow 
precipitates appeared. The precipitate was filtered off, washed with cold water and dried 
under vacuum overnight to provide the final product 1d as yellow solid (22 mg, 71% yield 
over two steps). 1H NMR (400 MHz, DMSO-d6) δ 2.42 (s, 3H, CH3), 3.87 (dd, J = 9.7, 1.7 Hz, 
1H, CH), 4.17 (dd, J = 9.6, 1.8 Hz, 1H, CH), 4.60 (d, J = 10.9 Hz, 1H, BnH), 4.95 (d, J = 
11.0 Hz, 1H, BnH), 7.42 (d, J = 7.3 Hz, 2H, ArH), 7.55 (td, J = 7.7, 1.7 Hz, 1H, ArH), 7.63 
(d, J = 6.7 Hz, 1H, ArH), 7.76 – 7.86 (m, 3H, ArH), 7.96 (s, 1H, ArH); 13C NMR (101 MHz, 








phenyl)diazenyl)benzyloxy) succinate (18e) 
Compound 17 (80 mg, 0.29 mmol) and 4e (130 mg, 0.36 mmol) were dissolved in DMF (2 
mL) under -20 oC and stirred over 10 min. NaH (60% in mineral oil, 11.6 mg, 0.29 mmol) 
was added, and the reaction mixture was stirred at -20 oC for 2 h. Afterwards, it was warmed 
to 0 oC (ice bath) and the stirring continued for another 2 h. The reaction mixture was 
quenched with cold water and then extracted with EtOAc (3 x 20 mL). The collected organic 
phases were washed with brine (3 x 50 mL), and dried with Na2SO4. The volatiles were 
evaporated and the product was purified by flash chromatography (EtOAc : petroleum ether, 
10:90, v/v) to provide pure 18e as yellow oil (54 mg, 34% yield). 1H NMR (500 MHz, 
CDCl3) δ 1.42 (s, 9H, Boc-H9), 3.65 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 4.48 (d, J = 12.0 Hz, 
1H, BnH), 4.55 (d, J = 2.3 Hz, 1H, CH), 4.85 (dd, J = 10.0, 2.4 Hz, 1H, CH), 4.93 (d, J = 
12.0 Hz, 1H, BnH), 5.38 (d, J = 10.0 Hz, 1H, NH), 7.36 (d, J = 8.8 Hz, 2H, ArH), 7.40 (d, J = 
7.6 Hz, 1H, ArH), 7.50 (t, J = 7.7 Hz, 1H, ArH), 7.80 (t, J = 1.8 Hz, 1H, ArH), 7.86 (d, J = 
7.9 Hz, 1H, ArH), 7.96 (d, J = 8.8 Hz, 2H, ArH); 13C NMR (126 MHz, CDCl3) δ 28.3, 52.6, 
52.9, 56.2, 72.4, 77.3, 80.4, 121.4, 122.4, 123.1, 124.5, 129.4, 131.0, 138.1, 150.7, 151.1 (d, J 
= 0.9 Hz), 152.6, 155.6, 169.7, 169.8. One C is missing due to overlap (CF3). HRMS (ESI+) 







To a solution of 18e (54 mg, 0.10 mmol) in dry DCM (2 mL), cooled in an ice-bath, 
trifluoroacetic acid (0.8 mL) was added dropwise. After 10 min, the ice-bath was removed 
and the reaction mixture was stirred at room temperature for 1.5 h until all the starting 
materials were consumed (TLC monitor). Volatiles were removed in vacuo to provide product 
19e which was used in the next step without further purification. Compound 19e was 
dissolved in THF (1 mL) and water (1 mL) and LiOH (14.4 mg, 0.60 mmol) was added. The 
reaction mixture was stirred at room temperature for 2 h. Volatiles were removed in vacuo 
and, residue was washed with EtOAc (1 mL) and acidified with 1 M HCl until yellow 
precipitates appeared. The precipitate was filtered off, washed with cold water and dried 
under vacuum overnight to provide the final product 1e as yellow solid (30 mg, 70% yield 
over two steps). 1H NMR (400 MHz, DMSO-d6) δ 3.88 (d, J = 9.7 Hz, 1H, CH), 4.17 (d, J = 
9.6 Hz, 1H, CH), 4.61 (d, J = 11.0 Hz, 1H, BnH), 4.96 (d, J = 11.0 Hz, 1H, BnH), 7.56 – 7.62 
(m, 3H, ArH), 7.67 (d, J = 7.1 Hz, 1H, ArH), 7.83 (d, J = 8.0 Hz, 1H, ArH), 8.00 – 8.04 (m, 
3H, ArH); 13C NMR (101 MHz, DMSO-d6) δ 53.2, 72.2, 75.0, 121.6, 121.9, 122.6, 124.5, 
129.2, 131.5, 139.5, 150.1, 150.5, 151.8, 168.4, 170.6. One C is missing due to CF3. 
19F NMR 
(376 MHz, DMSO-d6) δ -61.1 (s). HRMS (ESI+) calc for [M+H]




phenyl)diazenyl)benzyloxy) succinate (18f) 
Compound 17 (91 mg, 0.33 mmol) and 4f (120 mg, 0.42 mmol) were dissolved in DMF (2 
mL) under -20 oC and stirred over 10 min. NaH (60% in mineral oil, 13.2 mg, 0.33 mmol) 
was added, and the reaction mixture was stirred at -20 oC for 2 h. Afterwards, it was warmed 




quenched with cold water and then extracted with EtOAc (3 x 20 mL). The collected organic 
phases were washed with brine (3 x 50 mL), and dried with Na2SO4. The volatiles were 
evaporated and the product was purified by flash chromatography (EtOAc : petroleum ether, 
10:90, v/v) to provide pure 18f as yellow oil (50 mg, 31% yield). 1H NMR (500 MHz, CDCl3) 
δ 1.43 (s, 9H, Boc-H9), 2.46 (s, 3H, CH3), 3.64 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 4.48 (d, J 
= 12.1 Hz, 1H, BnH), 4.55 (d, J = 2.4 Hz, 1H, CH), 4.84 (dd, J = 10.0, 2.4 Hz, 1H, CH), 4.93 
(d, J = 12.1 Hz, 1H, BnH), 5.38 (d, J = 10.0 Hz, 1H, NH), 7.30 (d, J = 7.4 Hz, 1H, ArH), 7.38 
(dt, J = 7.6, 1.3 Hz, 1H, ArH), 7.41 (t, J = 8.0 Hz, 1H, ArH), 7.50 (t, J = 7.7 Hz, 1H, ArH), 
7.72 – 7.73 (m, 2H, ArH), 7.79 (s, 1H, ArH), 7.86 (dt, J = 8.0, 1.5 Hz, 1H, ArH); 13C NMR 
(126 MHz, DMSO-d6) δ 20.9, 28.0, 52.1, 52.4, 55.6, 71.5, 77.5, 78.8, 120.3, 121.6, 121.7, 
121.8, 122.5, 122.5, 129.3, 130.6, 132.3, 138.9, 139.0, 152.0, 155.3, 169.5, 169.5. HRMS 
(ESI+) calc for [M+H]+ (C25H32N3O7




To a solution of 18f (50 mg, 0.10 mmol) in dry DCM (2 mL), cooled in an ice-bath, 
trifluoroacetic acid (0.8 mL) was added dropwise. After 10 min, the ice-bath was removed 
and the reaction mixture was stirred at room temperature for 1.5 h until all the starting 
materials were consumed (TLC monitor). Volatiles were removed in vacuo to provide product 
19f which was used in the next step without further purification. Compound 19f was dissolved 
in THF (1 mL) and water (1 mL) and LiOH (14.4 mg, 0.60 mmol) was added. The reaction 
mixture was stirred at room temperature for 2 h. Volatiles were removed in vacuo and, residue 
was washed with EtOAc (1 mL) and acidified with 1 M HCl until yellow precipitates 
appeared. The precipitate was filtered off, washed with cold water and dried under vacuum 




1H NMR (400 MHz, DMSO-d6) δ 2.43 (s, 3H, CH3), 3.87 (d, J = 9.7 Hz, 1H, CH), 4.17 (d, J 
= 9.7 Hz, 1H, CH), 4.60 (d, J = 11.0 Hz, 1H, BnH), 4.95 (d, J = 11.0 Hz, 1H, BnH), 7.40 (d, J 
= 7.7 Hz, 1H, ArH), 7.47 – 7.52 (m, 1H, ArH), 7.56 (t, J = 7.7 Hz, 1H, ArH), 7.64 (d, J = 7.5 
Hz, 1H, ArH), 7.70 – 7.72 (m, 2H, ArH), 7.80 (d, J = 7.7 Hz, 1H, ArH), 7.98 (s, 1H, ArH); 
13C NMR (101 MHz, DMSO-d6) δ 20.9, 53.1, 72.3, 74.9, 120.2, 121.4, 122.4, 122.5, 129.1, 
129.3, 131.0, 132.2, 139.0, 139.4, 151.9, 152.0, 168.4, 170.5. HRMS (ESI+) calc for [M+H]+ 




phenyl)diazenyl)benzyloxy) succinate (18g) 
Compound 17 (90 mg, 0.32 mmol) and 4f (185 mg, 0.64 mmol) were dissolved in DMF (2 
mL) under -20 oC and stirred over 10 min. NaH (60% in mineral oil, 12.8 mg, 0.32 mmol) 
was added, and the reaction mixture was stirred at -20 oC for 2 h. Afterwards, it was warmed 
to 0 oC (ice bath) and the stirring continued for another 2 h. The reaction mixture was 
quenched with cold water and then extracted with EtOAc (3 x 20 mL). The collected organic 
phases were washed with brine (3 x 50 mL), and dried with Na2SO4. The volatiles were 
evaporated and the product was purified by flash chromatography (EtOAc : petroleum ether, 
10:90, v/v) to provide pure 18g as yellow oil (56 mg, 36% yield). 1H NMR (500 MHz, 
CDCl3) δ 1.42 (s, 9H, Boc-H9), 2.73 (s, 3H, CH3), 3.64 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 
4.49 (d, J = 12.1 Hz, 1H, BnH), 4.55 (d, J = 2.4 Hz, 1H, CH), 4.84 (dd, J = 9.9, 2.4 Hz, 1H, 
CH), 4.93 (d, J = 12.0 Hz, 1H, BnH), 5.39 (d, J = 9.9 Hz, 1H, NH), 7.25 – 7.28 (m, 1H, ArH), 
7.34 – 7.39 (m, 3H, ArH), 7.49 (t, J = 7.7 Hz, 1H, ArH), 7.62 (d, J = 8.0 Hz, 1H, ArH), 7.79 
(d, J = 1.9 Hz, 1H, ArH), 7.86 (dd, J = 8.0, 1.5 Hz, 1H); 13C NMR (126 MHz, DMSO-d6) δ 




131.5, 137.7, 138.9, 149.9, 152.4, 155.3, 169.5, 169.5. HRMS (ESI+) calc for [M+H]+ 




To a solution of 18g (56 mg, 0.11 mmol) in dry DCM (2 mL), cooled in an ice-bath, 
trifluoroacetic acid (0.8 mL) was added dropwise. After 10 min, the ice-bath was removed 
and the reaction mixture was stirred at room temperature for 1.5 h until all the starting 
materials were consumed (TLC monitor). Volatiles were removed in vacuo to provide product 
19g which was used in the next step without further purification. Compound 19g was 
dissolved in THF (1 mL) and water (1 mL) and LiOH (15.8 mg, 0.66 mmol) was added. The 
reaction mixture was stirred at room temperature for 2 h. Volatiles were removed in vacuo 
and, residue was washed with EtOAc (1 mL) and acidified with 1 M HCl until yellow 
precipitates appeared. The precipitate was filtered off, washed with cold water and dried 
under vacuum overnight to provide the final product 19 as yellow solid (27 mg, 69% yield 
over two steps). 1H NMR (400 MHz, DMSO-d6) δ 2.69 (s, 3H, CH3), 3.87 (dd, J = 9.6, 1.4 Hz, 
1H, CH), 4.17 (dd, J = 9.6, 1.4 Hz, 1H, CH), 4.60 (d, J = 11.0 Hz, 1H, BnH), 4.96 (d, J = 
11.0 Hz, 1H, BnH), 7.31 – 7.35 (m, 1H, ArH), 7.44 – 7.48 (m, 2H, ArH), 7.53 – 7.58 (m, 2H, 
ArH), 7.64 (d, J = 7.6 Hz, 1H, ArH), 7.79 (d, J = 7.8 Hz, 1H, ArH), 7.99 (s, 1H, ArH); 13C 
NMR (101 MHz, DMSO-d6) δ 17.2, 53.1, 72.3, 75.0, 115.1, 121.1, 122.9, 126.6, 129.1, 130.9, 
131.4, 131.5, 137.7, 139.4, 145.0, 152.3, 168.4, 170.6. HRMS (ESI+) calc for [M+H]
+ 









1.3 NMR spectra 
 












































































































































































































2. Photochemical data 
Room temperature UV-Vis absorption spectra were recorded on an Agilent 8453 UV-Vis 
Spectrophotometer using Uvasol grade solvents. Irradiation experiments were performed:  
312/365 nm: with a spectroline ENB - 280C/FE UV lamp; white light: Thor Labs OSL1 - EC 




Figure S41: UV/VIS spectra of p-CF3-azo-TBOA, 20 µM in DMSO, thermally adapted, 
irradiated with λ = 312 nm light for 120s and white light for 30s 
 
Figure S42: UV/VIS absorbance of p-CF3-azo-TBOA at λ = 317 nm, 20 µM in DMSO, 





Figure S43: 1H NMR spectrum of p-CF3-azo-TBOA, 1mg in 500 µl DMSO-d6. Top: thermal, 
middle: 30 min irradiation with 312 nm light, bottom, 60 min irradiation with 312 nm light 
 
Figure S44: 19F NMR spectrum of p-CF3-azo-TBOA, 1mg in 500 µl DMSO-d6. Top: thermal, 





Figure S45: UV/VIS absorbance of p-CF3-azo-TBOA, 20 µM in DMSO, irradiated with 365 
nm light and white light. 
 
 
Figure S46: UV/VIS spectra of p-MeO-azo-TBOA 20 µM in DMSO, thermally adapted, 
irradiated with λ = 365 nm light for 40 s and white light for 20 s. 
 
Figure S47: UV/VIS absorbance of p-MeO-azo-TBOA at λ = 354 nm, ~0.1 mM in DMSO in 





Figure S48: UV/VIS absorbance of p-MeO-azo-TBOA at λ = 353 nm, 20 µM in DMSO, 
irradiated with 365 nm light and white light 
 
Figure S49: UV/VIS spectra of p-MeO-azo-TBOA 20 µM in 50µM KPi pH = 7.4, 1% DMSO, 
thermally adapted, irradiated with λ=365 nm light for 40 s and white light for 2 0s. 
 
Figure S50: UV/VIS absorbance of p-MeO-azo-TBOA at λ = 354 nm, ~0.1 mM in KPi pH = 
7.4, 1% DMSO in quadruplo, measured for thermal cis-trans isomerization at 37 oC. The 





Figure S51: UV/VIS absorbance of p-MeO-azo-TBOA at λ = 353 nm, 20 µM in KPi pH = 
7.4, 1% DMSO, irradiated with 365 nm light and white light 
 
Figure S52: 1H NMR spectrum of p-MeO-azo-TBOA 1mg in 500 µl DMSO-d6, cis-trans 
ratio’s calculated from the 1H signals of Ar-CH2-O and O-CH-R2 protons. Top: thermal, cis-






Figure S53: UV/VIS spectra of p-HexO-azo-TBOA, 20 µM in DMSO, thermally adapted, 
irradiated with λ = 365 nm light for 30 s and white light for 40 s. 
 
Figure S54: UV/VIS absorbance of p-HexO-azo-TBOA at λ = 354 nm, ~0.1 mM in DMSO, 
measured in quadruplo for thermal cis-trans isomerization at 37 oC. 
 
Figure S55: UV/VIS absorbance of p-HexO-azo-TBOA at λ = 355 nm, 20 µM in DMSO, 





Figure S56: 1H NMR spectrum of p-HexO-azo-TBOA, 1mg in 500 µl DMSO-d6, cis-trans 
ratio’s calculated from the 1H signals of Ar-CH2-O protons. Top: thermal, cis-trans ratio 
2:98. Bottom: irradiated with λ = 365 nm light, cis-trans ratio 2:98.  
 
 
Figure S57: UV/VIS spectra of p-Me-azo-TBOA, 20 µM in DMSO, thermally adapted, 
irradiated with λ = 365 nm light for 80 s and white light for 80 s. 
 
Figure S58: UV/VIS absorbance of p-Me-azo-TBOA at λ = 340 nm, ~0.2 mM in DMSO in 





Figure S59: UV/VIS absorbance of p-Me-azo-TBOA at λ = 332 nm, 20 µM in DMSO, 
irradiated with 365 nm light and white light 
 
Figure S60: 1H NMR spectrum of p-Me-azo-TBOA, 1mg in 500 µl DMSO-d6, cis-trans 
ratio’s calculated from the 1H signals of Ar-CH2-O and O-CH-R2 protons. Top: thermal, cis-






Figure S61: UV/VIS spectra of p-CF3O-azo-TBOA, 20 µM in DMSO, thermally adapted, 
irradiated with λ = 312 nm light for 60 s and white light for 90 s. 
 
Figure S62: UV/VIS absorbance of p-CF3O-azo-TBOA at λ = 340 nm, ~0.2 mM in DMSO in 
quadruplo, measured for thermal cis-trans isomerization at 37 oC. 
 
Figure S63: UV/VIS absorbance of p-CF3O-azo-TBOA at λ = 324 nm, 20 µM in DMSO, 





Figure S64: 1H NMR spectrum of p-CF3O-azo-TBOA, 1mg in 500 µl DMSO-d6, cis-trans 
ratio’s calculated from the 1H signals of Ar-CH2-O and O-CH-R2 protons. Top: thermal, cis-
trans ratio 4:96. Bottom: irradiated with λ = 365 nm light, cis-trans ratio 71:29.  
 
 
Figure S65: UV/VIS spectra of m-Me-azo-TBOA, 20 µM in DMSO, thermally adapted, 





Figure S66: UV/VIS absorbance of m-Me-azo-TBOA at λ = 340 nm, ~0.2 mM in DMSO in 
quadruplo, measured for thermal cis-trans isomerization at 37 oC. 
 
Figure S67: UV/VIS absorbance of m-Me-azo-TBOA at λ = 326 nm, 20 µM in DMSO, 






Figure S68: 1H NMR spectrum of m-Me-azo-TBOA, 1mg in 500 µl DMSO-d6, cis-trans 
ratio’s calculated from the 1H signals of Ar-CH2-O and O-CH-R2 protons. Top: thermal, cis-
trans ratio 3:97. Bottom: irradiated with λ = 312 nm light, cis-trans ratio 86:14.  
 
 
Figure S69: UV/VIS spectra of o-Me-azo-TBOA 20 µM in DMSO, thermally adapted, 





Figure S70: UV/VIS absorbance of o-Me-azo-TBOA at λ = 340 nm, ~0.2 mM in DMSO in 
quadruplo, measured for thermal cis-trans isomerization at 37 oC. 
 
Figure S71: UV/VIS absorbance of o-Me-azo-TBOA at λ = 330 nm, 20 µM in DMSO, 





Figure S72: 1H NMR spectrum of o-Me-azo-TBOA, 1mg in 500 µl DMSO-d6, cis-trans 
ratio’s calculated from the 1H signals of Ar-CH2-O and O-CH-R2 protons. Top: thermal, cis-





3. Biological evaluation 
3.1 DNA manipulation, protein purification and concentration determination. 
As described in Jensen et al., 3 
 
Proteoliposome preparation 
E. coli total lipid extract was purified with aceton and diethylether, both with 1 mM DTT. The 
E. coli lipids was mixed with L-(α)-phosphatidylchloine Egg chicken in a ratio of 3:1. Finally 
they were dissolved in 50 mM KPi pH 7.0 (20 mg/ml) and frozen in liquid N2. Subsequently 
the lipid mixture was extruded with a 400 nm filter 11 times and diluted with 50mM KPi (pH 
7.0) to a final concentration of 4 mg/ml. The mixture was titrated with 10% triton X-100 until 
Rsat. 100 µg of the purified protein and lipids was mixed in a ratio of 1:1600 (w:w) and 
incubated at room temperature for 30 minutes. Biobeads were added four times (200 mg for 5 
mL 4 mg/ml lipid solution) for 0.5 h, 1 h, overnight and 2 h at 4 oC. The biobeads were 
removed by filtration. The proteoliposomes where spun down for 20 min at 80000 Cpm and 
subsequently resuspended in 50 mM KPi pH 7.0 at a concentration of 16.7 µg protein per 500 
µL and freeze-thawed for four cycles. The proteoliposomes are stored in liquid N2. 
 
3.2 Uptake assay 
The proteoliposomes were thawed, extruded with a 400 nm filter, spin down for 20 minutes at 
80000 Cpm and subsequently resuspended in 50 mM KPi pH 7.0 at a concentration of 16.7 µg 
protein per 120 µL buffer. 1800 µL of 50 mM NaPi pH 7.0, 1µM [14C]aspartic acid and 3 µM 
Valinomycin was stirred in a tube at 30oC and to that the transport assay was started by the 
addition of 10 µL proteoliposomes (1.39 µg protein) and either pure DMSO or a DMSO 
solution of inhibitor (final DMSO concentration 1%). From this mixture, at several time 




subsequently filtering over a Protran BA 85-Whatman filter. The filter was washed by 2 mL 
cold 100 mM LiCl and transported to a cup. (Optionally the assay was irradiated with 365 nm 
UV light for 45 s to switch compounds p-MeO-azo-TBOA at a concentration of 50 mM from 
trans to cis or irradiated with white light using a Thor Labs OSL1 - EC Fiber Illuminator to 
switch compound p-MeO-azo-TBOA at a concentration of 50 mM from cis to trans). To the 
cup, 2 mL of scintillation liquid was added and the activity of the cup was measured with a 
















Figure S73: [14C]Aspartate uptake assay, with uninhibited uptake, 10 µM non-irradiated p-



















Figure S74: [14C]Aspartate uptake assay, with uninhibited uptake, 10 µM non-irradiated p-
















Figure S75: [14C]Aspartate uptake assay, with uninhibited uptake, 10 µM non-irradiated p-

















Figure S76: [14C]Aspartate uptake assay, with uninhibited uptake, 10 µM non-irradiated p-



















Figure S77: [14C]Aspartate uptake assay, with uninhibited uptake, 10 µM non-irradiated p-
















Figure S78: [14C]Aspartate uptake assay, with uninhibited uptake, 10 µM non-irradiated m-



















Figure S79: [14C]Aspartate uptake assay, with uninhibited uptake, 10 µM non-irradiated o-
















Figure S80: [14C]Aspartate uptake assay, with uninhibited uptake and 10 µM TFB-TBOA. 



















Figure S81: [14C]Aspartate uptake assay, with uninhibited uptake and increasing 























Figure S82: [14C]Aspartate uptake assay, with uninhibited uptake and increasing 




















Figure S83: [14C]Aspartate uptake assay, with uninhibited uptake and increasing 























Figure S84: [14C]Aspartate uptake assay, with uninhibited uptake and increasing 




















Figure S85: [14C]Aspartate uptake assay, with uninhibited uptake and increasing 





















Figure S86: [14C]Aspartate uptake assay, with uninhibited uptake and several concentrations 
of p-MeO-azo-TBOA in different trans-cis ratios. A 0.5 mM stock solution was irradiated and 
samples were removed at several timepoints. From the 0.5 mM solution, 20 μL was diluted 5 
times in DMSO to a total volume of 100 μL and OD340 was recorded in a transparent 96 well 
plate. The 0.5 mM solution was diluted 50 times with buffer to a final concentration of 10 μM 















Figure S87: [14C]Aspartate uptake assay, with uninhibited uptake, continuously irradiated 
with UV light for 6 minutes and continuously irradiated with white light for 6 minutes. All 






















Figure S88: [14C]Aspartate uptake assay, with uninhibited uptake and a control of 50 μM 
trans p-MeO-azo-TBOA without further switching. Irradiation reversibly controls the 
transport, starting with p-MeO-azo-TBOA in trans, Irradiated for 45 s with UV light after 2.5 
minutes, 45 s white light after 5.75 minutes and 45 s UV light after 9 minutes. All experiments 



















Figure S89: [14C]Aspartate uptake assay, with uninhibited uptake and a control of 50µM cis 
p-MeO-azo-TBOA without further switching. Irradiation reversibly controls the transport, 




45 s UV light after 5.75 minutes and 45 s white light after 9 minutes. All experiment were 
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Figure S90: [14C]Aspartate uptake assay of p-MeO-azo-TBOA. A 0.5 mM DMSO solution of 
p-MeO-azo-TBOA was irradiated with UV (120 s), white light (180 s), UV light (120 s) and 
white light (180 s) and after every irradiation step a samples was taken and diluted 50 times 





Isothermal Titration Calorimetry 
For the binding experiments, GltTk was purified as described above, using a buffer containing 
10 mM HEPES pH 8.0, 100 mM KCl and 0.15% DM on the size exclusion column. The 
solution of purified protein was supplemented with 300 mM NaCl and 250 μL of solution 
were loaded into the measuring cell of a small-volume NANO ITC (TA Instruments) at 
concentrations between 5 μM and 15 μM. L-Aspartate, TFB-TBOA, p-MeO-azo-TBOA and 
p-HexO-azo-TBOA were dissolved in purification buffer supplemented with 300 mM NaCl 
and loaded into the titration syringe at concentrations ranging from 100 μM to 400 μM. After 
equilibrating the cell at 25 °C, aliquots of 1 µL were injected every 1.5 - 2.5 minutes 
depending on the time needed for the signal to return to the baseline value after each injection. 
The binding isotherms were analyzed with NanoAnalyze (TA Instruments) using the 
independent binding-site model. The Kd values obtained in different experiments were 










Figure S91: ITC measurement of L-Aspartate 
 
 







Figure S93: ITC measurement of trans-p-MeO-azo-TBOA 
 
 





Figure S95: ITC measurement of trans-p-HexO-azo-TBOA  
 




4 Statistical analysis 
 
All data processing of the biological evaluation was done using Graphpad Prism 6 software. 
Of the linear region of [14C]aspartate uptake rates, slopes were calculated using the linear 
regression function and subsequently normalized to the uninhibited uptake rate, which was set 
at 100%.  The calculation of IC50 values was performed using the non-linear regression 
function, without any constraints. Statistical significance was determined using a two-sided t-
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